• DHEA A. RAMADHANI Pharmacy Department, Sebelas Maret University, Surakarta 57126, Indonesia
  • ADI YUGATAMA Pharmacy Department, Sebelas Maret University, Surakarta 57126, Indonesia
  • DIAN E. ERMAWATI Pharmacy Department, Sebelas Maret University, Surakarta 57126, Indonesia



NSAID, Solid dispersion, Anti-inflammatory activity, Systematic review


Objective: NSAIDs are very hydrophobic drugs and have low solubility. This causes the bioavailability of NSAIDs to be low in the body thus affect its anti-inflammatory activity. There has been some primary research proven that solid dispersion can increase the solubility and anti-inflammatory activity of NSAIDs. Moreover, there are not researches explaining the effect of a solid dispersion system on the anti-inflammatory activity of NSAIDs. Therefore, it is necessary to conduct a review to assess the effect of the solid dispersion system on the solubility and anti-inflammatory activity of NSAIDs systematically.

Methods: This was systematic review research, where the data were originated from PubMed and Science Direct with the keywords ‘NSAID’, ‘solid dispersion’, and ‘drug effect’. The inclusion criteria formulated were English-language papers, published in 2010–2020, and primary research that conducted in vivo anti-inflammatory testing. The appropriate papers by the inclusion criteria were assessed its quality by the SYRCLE’s tool. Data was analyzed narratively.

Results: The results were eight papers under the inclusion criteria. As a whole is known modification of solid dispersion can increase the dissolution profile of NSAIDs. This is because the polymer used can increase the wetting of drug particles, thereby being able to increase the solubility of NSAIDs.

Conclusion: The anti-inflammatory activity of NSAIDs by solid dispersion systems are increases compared to NSAIDs without solid dispersions.


Download data is not yet available.


1. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The “High solubility” Definition of the current FDA guidance on biopharmaceutical classification system may be too strict for acidic drugs. Pharm Res 2004;21:293–9.
2. Ansel HC, Ibrahim F. Pengantar sediaan farmasi. Jakarta: Penerbit Universitas Indonesia; 1989.
3. Shargel L, Wu Pong S, Yu A. Applied biopharmaceutics and pharmacokinetics. 5th ed. New York: McGraw-Hill Companies, Incorporated; 2004.
4. Douroumis D, Fahr A. Drug delivery strategies for poorly water-soluble drugs. Chichester: Wiley; 2012.
5. Cid AG, Simonazzi A, Palma SD, Bermudez JM. Solid dispersion technology as a strategy to improve the bioavailability of poorly soluble drugs. Thera Delivery Future Medicine Ltd 2019;10:363–82.
6. Chen L, Dang Q, Liu C, Chen J, Song L, Chen X. Improved dissolution and anti-inflammatory effect of ibuprofen by solid dispersion. Front Med China 2012;6:195–203.
7. Swidan S. Design, formulation and evaluation of piroxicam capsules prepared by solid dispersion technique. Br J Pharm Res 2013;3:108–34.
8. Ghanavati R, Taheri A, Homayouni A. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier. Mater Sci Eng C 2017;72:501–11.
9. Shi NQ, Wang SR, Zhang Y, Huo JS, Wang LN, Cai JH, et al. Hot melt extrusion technology for improved dissolution, solubility and “spring-parachute” processes of amorphous self-micellizing solid dispersions containing BCS II drugs indomethacin and fenofibrate: profiles and mechanisms. Eur J Pharm Sci 2019;130:78–90.
10. Yadav PS, Kumar V, Singh UP, Bhat HR, Mazumder B. Physicochemical characterization and in vitro dissolution studies of solid dispersions of ketoprofen with PVP K30 and d-mannitol. Saudi Pharm J 2013;21:77–84.
11. Shazly GA. Effect of sulindac binary system on in vitro and in vivo release profiles: an assessment of polymer type and its ratio. Biomed Res Int 2016:1-9.
12. O’Connor AM, Sargeant JM. Critical appraisal of studies using laboratory animal models. ILAR J 2014;55:405–17.
13. Zeng X, Zhang Y, Kwong JSW, Zhang C, Li S, Sun F, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med 2015;8:2–10.
14. Hooijmans CR, Rovers MM, De Vries RBM, Leenaars M, Ritskes Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol 2014;14:1–9.
15. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration; 2011.
16. Sridevi S, Diwan PVR. Optimized transdermal delivery of ketoprofen using pH and hydroxypropyl-?-cyclodextrin as co-enhancers. Eur J Pharm Biopharm 2002;54:151–4.
17. Jana S, Ali SA, Nayak AK, Sen KK, Basu SK. Development of topical gel containing aceclofenac-crospovidone solid dispersion by “Quality by Design (QbD)” approach. Chem Eng Res Des 2014;92:2095–105.
18. Malipeddi VR, Dua K, Awasthi R. Development and characterization of solid dispersion-microsphere controlled release system for poorly water-soluble drug. Drug Delivery Transl Res 2016;6:540–50.
19. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60.
20. Alshehri S, Shakeel F, Ibrahim M, Elzayat E, Altamimi M, Shazly G, et al. Influence of the microwave technology on solid dispersions of mefenamic acid and flufenamic acid. PLoS One 2017;12:1–18.
21. Barreiro Iglesias R, Alvarez Lorenzo C, Concheiro A. Poly(acrylic acid) microgels (carbopol® 934)/surfactant interactions in aqueous media-part I: nonionic surfactants. Int J Pharm 2003;258:165–77.
22. Thakral S, Thakral NK, Majumdar DK. Eudragit®: a technology evaluation. Expert Opin Drug Delivery 2013;10:131–49.
23. Kojima T, Higashi K, Suzuki T, Tomono K, Moribe K, Yamamoto K. Stabilization of a supersaturated solution of mefenamic acid from a solid dispersion with EUDRAGIT® EPO. Pharm Res 2012;29:2777–91.
24. Alshehri S, Shakeel F, Elzayat E, Almeanazel O, Altamimi M, Shazly G, et al. Rat palatability, pharmacodynamics effect and bioavailability of mefenamic acid formulations utilizing hot-melt extrusion technology. Drug Dev Ind Pharm 2019;45:1610–6.
25. Alshehri SM, Park JB, Alsulays BB, Tiwari R V, Almutairy B, Alshetaili AS, et al. Mefenamic acid taste-masked oral disintegrating tablets with enhanced solubility via molecular interaction produced by hot melt extrusion technology. J Drug Delivery Sci Technol 2015;27:18–27.
26. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm Res 2000;17:397–404.
27. Choi JS, Lee DH, Ahn J Bin, Sim S, Heo KS, Myung CS, et al. Therapeutic effects of celecoxib polymeric systems in rat models of inflammation and adjuvant-induced rheumatoid arthritis. Mater Sci Eng C 2020;114:1-10.
28. Choi JS, Ahn J Bin, Park JS. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats. Int J Pharm 2019;555:135–45.
29. Shazly G, Badran M, Zoheir K, Alomrani A. Utilization of spray drying technique for improvement of dissolution and anti-inflammatory effect of meloxicam. Pak J Pharm Sci 2015;28:103–11.
30. Rowe RC, Sheskey PJ, Owen SC, Association AP. Handbook of pharmaceutical excipients. Sixth Edition. Pharmaceutical Press; 2009.
31. Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm 2002;231:131–44.
32. Choi JS, Ahn J Bin, Park JS. Amorphous multi-system of celecoxib improves its anti-inflammatory activity in vitro and oral absorption in rats. Int J Pharm 2019;555:135–45.



How to Cite




Review Article(s)

Most read articles by the same author(s)